CBER Director Marks’ Intervention On Sarepta Gene Therapy Filing Decision Appears To Backfire
Executive Summary
Former OTAT Director Wilson Bryan says Peter Marks’ order to file Sarepta’s DMD gene therapy application was mainly a public relations move, which does not seem to have worked in the FDA’s favor. Upcoming advisory committee could now involve as much scrutiny of the agency as the application itself.
You may also be interested in...
Is Sarepta’s Gene Therapy Elevidys Casting Doubt On A Popular DMD Endpoint?
Sponsors don’t seem worried that US FDA will become skeptical of the North Star Ambulatory Assessment (NSAA) because Sarepta says it was not sensitive enough to detect patient changes in the confirmatory trial for its DMD gene therapy Elevidys.
Elevidys And The EMBARK Trial: Is Another Advisory Committee Meeting Coming?
Sarepta says another public meeting is not necessary to expand the label for its DMD gene therapy, but the missed primary endpoint may require input from experts outside the FDA, and the situation renews the spotlight on CBER Director Peter Marks and his initial approval decision.
Elevidys’ Age-Restricted Indication Not Negotiable, CBER’s Peter Marks Told Sarepta
FDA team held several internal meetings on the gene therapy after the 12 May advisory committee, culminating in a teleconference with Sarepta in which the CBER director outlined his accelerated approval decision and reiterated recommendations to modify the ongoing EMBARK trial to better ensure confirmation of benefit. Pink Sheet's Drug Review Profile dives into the story behind the Elevidys review.